{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:18:54Z","timestamp":1740136734971,"version":"3.37.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1124\/jpet.123.001851","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T20:20:13Z","timestamp":1703276413000},"page":"774-787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Parthenolide As a Therapeutic for Disseminated Canine Neoplasms"],"prefix":"10.1016","volume":"388","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-0909","authenticated-orcid":false,"given":"Lisa J.","family":"Schlein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel A.","family":"Brill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel V.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0476-6575","authenticated-orcid":false,"given":"Kristen B.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis K.","family":"Meuten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas H.","family":"Thamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.001851_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/jsap.12354","article-title":"Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma","volume":"56","author":"Cannon","year":"2015","journal-title":"J Small Anim Pract"},{"key":"10.1124\/jpet.123.001851_bib2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/001857879903400408","article-title":"Feverfew","volume":"34","author":"Chavez","year":"1999","journal-title":"Hosp Pharm"},{"issue":"Suppl 9","key":"10.1124\/jpet.123.001851_bib3","first-page":"637","article-title":"The mass-action law-based new computer software, CompuSyn, for automated simulation of synergism and antagonism in drug combination studies","volume":"67","author":"Chou","year":"2007","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.123.001851_bib4","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.bbamcr.2012.06.019","article-title":"Glutathione and modulation of cell apoptosis","volume":"1823","author":"Circu","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.123.001851_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/toxsci\/kfp131","article-title":"Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance","volume":"111","author":"Cohen","year":"2009","journal-title":"Toxicol Sci"},{"key":"10.1124\/jpet.123.001851_bib6","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/vco.12252","article-title":"Clinical prognostic factors in canine histiocytic sarcoma","volume":"15","author":"Dervisis","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"10.1124\/jpet.123.001851_bib7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1354\/vp.42-5-618","article-title":"Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma","volume":"42","author":"Dickerson","year":"2005","journal-title":"Vet Pathol"},{"key":"10.1124\/jpet.123.001851_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00428-005-1264-9","article-title":"NF-kB in development and progression of human cancer","volume":"446","author":"Dolcet","year":"2005","journal-title":"Virchows Arch"},{"key":"10.1124\/jpet.123.001851_bib9","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/0006-2952(84)90598-7","article-title":"The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation","volume":"33","author":"Drew","year":"1984","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.123.001851_bib10","doi-asserted-by":"crossref","first-page":"10021","DOI":"10.1074\/jbc.M115.700591","article-title":"Targeting thioredoxin reductase by parthenolide contributes to inducing apoptosis of HeLa cells","volume":"291","author":"Duan","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.123.001851_bib11","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.drudis.2013.05.005","article-title":"Parthenolide: from plant shoots to cancer roots","volume":"18","author":"Ghantous","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.123.001851_bib12","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1182\/blood-2007-05-090621","article-title":"An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells","volume":"110","author":"Guzman","year":"2007","journal-title":"Blood"},{"key":"10.1124\/jpet.123.001851_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.vetimm.2014.02.016","article-title":"Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications","volume":"159","author":"Ito","year":"2014","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1124\/jpet.123.001851_bib14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.canlet.2013.03.007","article-title":"Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer","volume":"335","author":"Kim","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.123.001851_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2017-10-812495","article-title":"Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes","volume":"131","author":"Kommalapati","year":"2018","journal-title":"Blood"},{"key":"10.1124\/jpet.123.001851_bib16","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.exphem.2006.04.013","article-title":"Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation","volume":"34","author":"Lamerato-Kozicki","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1124\/jpet.123.001851_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ddr.21441","article-title":"Actinomycin-D and dimethylamino-parthenolide synergism in treating human pancreatic cancer cells","volume":"79","author":"Lamture","year":"2018","journal-title":"Drug Dev Res"},{"key":"10.1124\/jpet.123.001851_bib18","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"3B","key":"10.1124\/jpet.123.001851_bib19","first-page":"2425","article-title":"The thioredoxin-thioredoxin reductase system: over-expression in human cancer","volume":"23","author":"Lincoln","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1124\/jpet.123.001851_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2017","article-title":"The dog as a possible animal model for human non-Hodgkin lymphoma: a review","volume":"31","author":"Marconato","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1124\/jpet.123.001851_bib21","doi-asserted-by":"crossref","first-page":"E194","DOI":"10.1111\/vco.12373","article-title":"Association of prognostic features and treatment on survival time of dogs with systemic mastocytosis: a retrospective analysis of 40 dogs","volume":"16","author":"Moirano","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"10.1124\/jpet.123.001851_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0300985813510413","article-title":"A review of histiocytic diseases of dogs and cats","volume":"51","author":"Moore","year":"2014","journal-title":"Vet Pathol"},{"key":"10.1124\/jpet.123.001851_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1746-6148-8-128","article-title":"Constitutive phosphorylation of the mTORC2\/Akt\/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines","volume":"8","author":"Murai","year":"2012","journal-title":"BMC Vet Res"},{"key":"10.1124\/jpet.123.001851_bib24","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/1040638711408064","article-title":"Polymerase chain reaction-based species verification and microsatellite analysis for canine cell line validation","volume":"23","author":"O\u2019Donoghue","year":"2011","journal-title":"J Vet Diagn Invest"},{"key":"10.1124\/jpet.123.001851_bib25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ajh.23459","article-title":"Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management","volume":"88","author":"Pardanani","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1124\/jpet.123.001851_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/0973-7847.79105","article-title":"Feverfew (Tanacetum parthenium L.): a systematic review","volume":"5","author":"Pareek","year":"2011","journal-title":"Pharmacogn Rev"},{"key":"10.1124\/jpet.123.001851_bib27","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1038\/sj.onc.1203768","article-title":"Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide","volume":"19","author":"Patel","year":"2000","journal-title":"Oncogene"},{"key":"10.1124\/jpet.123.001851_bib28","doi-asserted-by":"crossref","first-page":"33542","DOI":"10.1074\/jbc.M113.511170","article-title":"Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells","volume":"288","author":"Pei","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.123.001851_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202100080","article-title":"Codelivery of paclitaxel and parthenolide in discoidal bicelles for a synergistic anticancer effect: structure matters","volume":"2","author":"Rad","year":"2022","journal-title":"Adv Nanobiomed Res"},{"key":"10.1124\/jpet.123.001851_bib30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/03009858221092017","article-title":"Review: NF-kB activation in canine cancer","volume":"59","author":"Schlein","year":"2022","journal-title":"Vet Pathol"},{"key":"10.1124\/jpet.123.001851_bib31","doi-asserted-by":"crossref","first-page":"368","DOI":"10.22205\/sijbs\/2016\/v2\/i4\/103443","article-title":"Function of nuclear factor kappa B (NF-kB) in human diseases- a review","volume":"2","author":"Serasanambati","year":"2016","journal-title":"South Indian J Biol Sci"},{"key":"10.1124\/jpet.123.001851_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1939-1676.2007.tb02937.x","article-title":"CCNU for the treatment of dogs with histiocytic sarcoma","volume":"21","author":"Skorupski","year":"2007","journal-title":"J Vet Intern Med"},{"key":"10.1124\/jpet.123.001851_bib33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/ph13080194","article-title":"Parthenolide as cooperating agent for anti-cancer treatment of various malignancies","volume":"13","author":"Sztiller-Sikorska","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1124\/jpet.123.001851_bib34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3390\/genes10070505","article-title":"Activating mutations in PTPN11 and KRAS in canine histiocytic sarcomas","volume":"10","author":"Takada","year":"2019","journal-title":"Genes (Basel)"},{"key":"10.1124\/jpet.123.001851_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cancergencyto.2007.07.017","article-title":"Mutation of the PTEN gene in a human hepatic angiosarcoma","volume":"178","author":"Tate","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1124\/jpet.123.001851_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00755791","article-title":"A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured\/isolated cells: performance study of a new miniaturized protocol","volume":"10","author":"Vandeputte","year":"1994","journal-title":"Cell Biol Toxicol"},{"key":"10.1124\/jpet.123.001851_bib37","article-title":"Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"key":"10.1124\/jpet.123.001851_bib38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/jps.2600620244","article-title":"Tumor inhibitory agent from Magnolia grandiflora (Magnoliaceae). I. Parthenolide","volume":"62","author":"Wiedhopf","year":"1973","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.123.001851_bib39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2174\/1389557514666140219113509","article-title":"Combined effect of parthenolide and various anti-cancer drugs or anticancer candidate substances on malignant cells in vitro and in vivo","volume":"14","author":"Wyr\u0119bska","year":"2014","journal-title":"Mini Rev Med Chem"},{"key":"10.1124\/jpet.123.001851_bib40","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/0008-5472.CAN-12-0440","article-title":"INK4a\/ARF [corrected] inactivation with activation of the NF-\u03baB\/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma","volume":"72","author":"Yang","year":"2012","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.123.001851_bib41","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1089\/ars.2020.8213","article-title":"Natural molecules targeting thioredoxin system and their therapeutic potential","volume":"34","author":"Zhang","year":"2021","journal-title":"Antioxid Redox Signal"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524172102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524172102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.001851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:17:49Z","timestamp":1739978269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524172102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0022356524172102"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.001851","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parthenolide As a Therapeutic for Disseminated Canine Neoplasms","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.001851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}